Table of Contents
Overview
New York, NY – June 11, 2025 – Global Cord Blood Banking Services Market size is expected to be worth around US$ 54.8 billion by 2034 from US$ 27.1 billion in 2024, growing at a CAGR of 7.3% during the forecast period 2025 to 2034. In 2023, North America led the market, achieving over 39.6% share with a revenue of US$ 10.7 Billion.
The global cord blood banking services market is witnessing steady growth, driven by rising awareness of stem cell therapies and increasing demand for regenerative medicine. Cord blood, collected from the umbilical cord immediately after birth, is a rich source of hematopoietic stem cells used in the treatment of over 80 life-threatening diseases, including leukemia, lymphoma, and sickle cell anemia. The adoption of cord blood banking is gaining momentum as more families recognize its long-term therapeutic potential.
Private cord blood banks dominate the market due to the rising preference for personalized stem cell storage. However, public banks also play a vital role in facilitating allogeneic transplants and supporting global donor registries. The U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other global health authorities continue to regulate the processing and storage of cord blood, ensuring high safety and quality standards.
Advancements in cryopreservation, improved collection techniques, and expanding clinical trials involving stem cell-based therapies are further accelerating market growth. North America holds the largest market share, followed by Europe and Asia-Pacific, where increasing birth rates and improving healthcare infrastructure are enhancing market penetration.
The cord blood banking industry is evolving toward integrated services that include tissue banking, genetic screening, and long-term biological storage solutions. As research in cell therapy advances, cord blood banking is expected to remain a cornerstone of personalized and regenerative medicine.
Key Takeaways
- In 2024, the global cord blood banking services market generated a revenue of approximately US$ 1 billion and is projected to reach US$ 54.8 billion by 2033, expanding at a compound annual growth rate (CAGR) of 7.3%.
- The service segment is categorized into collection & transportation, processing, analysis, and storage. Among these, the processing segment emerged as the leading contributor in 2023, accounting for 42.8% of the total market share.
- Based on component, the market is segmented into cord blood and cord tissue. Cord blood remained the dominant component, holding a substantial share of 59.3%.
- With respect to application, the market is divided into cancer, diabetes, blood disorders, immune disorders, metabolic disorders, and others. The cancer segment led the market, capturing the highest revenue share of 36.4%, reflecting the rising use of stem cell therapies in oncology.
- In terms of end-users, the market is segmented into hospitals, pharmaceutical & biotechnology companies, and academic & research institutes. The hospital segment accounted for the largest revenue share of 51.7%, driven by high procedural volumes and growing awareness among healthcare providers.
- Regionally, North America maintained its dominance in 2023, commanding 39.6% of the global market share, supported by advanced healthcare infrastructure, strong regulatory frameworks, and higher rates of cord blood banking awareness.
Segmentation Analysis
- Service Analysis: In 2023, the processing segment led the cord blood banking services market with a 42.8% share, driven by advancements in cryopreservation, transportation, and analysis techniques. As demand for high-quality stem cell processing rises, this segment is projected to grow steadily. Increasing cases of genetic disorders and stricter regulatory requirements are prompting service providers to enhance processing standards. Growth in emerging markets and evolving cell storage methods are expected to support the segment’s expansion over the coming years.
- Component Analysis: Cord blood accounted for 59.3% of the market share, largely due to rising awareness of its medical potential. Parents are increasingly opting to store cord blood stem cells, recognizing their role in treating various diseases. While cord blood leads, ongoing research into the regenerative potential of cord tissue is generating parallel interest. Growing clinical trial success, investment in stem cell technologies, and government-backed initiatives are anticipated to further drive demand for both cord blood and cord tissue storage services.
- Application Analysis: The cancer application segment dominated with a 36.4% revenue share, owing to the increasing use of cord blood stem cells in treating hematologic malignancies like leukemia and lymphoma. The segment’s growth is fueled by progress in immunotherapy and regenerative treatments. Rising global cancer incidence, greater clinical trial activity, and collaborative research among academic and healthcare institutions are contributing to expanding adoption. Enhanced therapeutic outcomes are likely to position cancer as the leading application area in the coming years.
- End-user Analysis: Hospitals led the end-user segment with 51.7% of market revenue in 2023, reflecting the integration of stem cell therapies into routine clinical practice. The segment’s expansion is supported by the growing use of regenerative medicine for conditions such as cancers and immune disorders. Collaborations between hospitals and cord blood banks are increasing, supported by active clinical trials and advancements in therapy protocols. The hospital sector is anticipated to remain dominant due to infrastructure readiness and wider access to stem cell treatments.
Market Segments
By Service
- Collection & Transportation
- Processing
- Analysis
- Storage
By Component
- Cord Tissue
- Cord Blood
By Application
- Diabetes
- Cancer
- Blood Disorder
- Immune Disorder
- Metabolic Disorder
- Others
By End-user
- Hospitals
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
Regional Analysis
North America led the cord blood banking services market in 2023, accounting for 39.6% of the global revenue share. This dominance can be attributed to heightened awareness of stem cell therapies, robust investments in regenerative medicine, and the increasing number of cord blood transplants for conditions such as leukemia and lymphoma. Rising adoption by expectant parents and favorable healthcare infrastructure further propelled the market. In April 2022, Global Cord Blood Corporation announced its acquisition of Cellenkos, Inc., gaining rights to its therapeutic pipeline—a strategic move reflecting the region’s active industry consolidation and expansion efforts.
Asia Pacific is anticipated to register the fastest compound annual growth rate (CAGR) over the forecast period. This growth is driven by increased healthcare investments, expanding awareness of stem cell applications, and proactive efforts by countries like China, India, and Japan. In October 2024, Cordlife Group Limited introduced an AI-powered model to predict CD34+ cell counts in cord blood, improving selection accuracy and transplant outcomes. Advancements in AI, along with growing regulatory support and public-private partnerships, are expected to significantly boost the region’s market growth and service efficiency.
Emerging Trends
- Rising Inventory of Public and Private Units: The total number of cord blood units stored worldwide has grown substantially. Currently, about 800,000 units are held in public banks, and approximately 4 million units are stored in private family banks, reflecting increasing parental interest in preserving these cells for future needs.
- Focus on Genetic Diversity: Efforts to improve match rates for all patients have led to a push for more units from varied ethnic backgrounds. In the U.S. registry alone, over 246,500 cord blood units are available, with more than 130,000 units from genetically diverse donors added by 2024.
- Advances in Cell Expansion Technologies: New laboratory methods are being developed to multiply stem cells from a single cord blood unit. These techniques aim to overcome the challenge that only about 10 % of collected units have enough cells for adult transplants, potentially broadening adult treatment options without needing multiple units.
- Regulatory Support and National Inventories: Legislation such as the Stem Cell Therapeutic and Research Act (2005, reauthorized in 2010, 2015, and 2021) has backed the National Cord Blood Inventory. The program’s goal is to collect and store at least 150,000 high-quality units for patients lacking family matches, ensuring steady public bank growth.
Use Cases
- Treatment of Blood Disorders: Cord blood stem cells are widely used to treat leukemia, lymphoma, and inherited blood diseases. In 2022, the U.S. reported 5,365 unrelated and 3,981 related bone marrow and cord blood transplants, underscoring their clinical importance in hematopoietic cell transplantation.
- Support for Patients Lacking Family Matches: Approximately 70 % of patients in need of a transplant do not have a fully matched family donor. For these patients, unrelated cord blood units offer a vital alternative, often requiring less stringent matching criteria than adult marrow donors.
- Regenerative Medicine Research: Public cord blood banks make selected units available for research studies aimed at new therapies. Under U.S. federal programs, thousands of units are allocated each year to research projects investigating uses such as immune modulation and tissue repair.
- Pediatric Transplants: Cord blood transplants are particularly suited to children due to smaller cell dose requirements. Over 30,000 patients worldwide have benefited from cord blood transplantation since the first unrelated-donor transplant in 1990, demonstrating its proven safety and efficacy in pediatric care.
Conclusion
The global cord blood banking services market is positioned for sustained growth, driven by rising awareness of stem cell applications, advancements in regenerative medicine, and increasing clinical adoption. Key market segments including processing services, cord blood components, and cancer-related applications are expanding rapidly, supported by evolving technologies and favorable regulatory environments.
North America leads in adoption, while Asia Pacific is expected to witness the fastest growth. Emerging trends such as AI integration, genetic diversity initiatives, and public inventory programs are enhancing market potential. As therapeutic and research use cases expand, cord blood banking is set to remain integral to modern personalized healthcare strategies.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
